Publikationen, an denen er mitarbeitet SANTIAGO MUÑOZ FERNANDEZ (24)

2024

  1. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

    Journal of Clinical Medicine, Vol. 13, Núm. 5

  2. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

    Medicina Clinica, Vol. 162, Núm. 10, pp. 470-476

  3. Raynaud's phenomenon and digital ischaemia induced by ixekizumab

    Rheumatology (Oxford, England), Vol. 63, Núm. 1

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. POS0793-HPR Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 689.2-690

  3. Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies

    Revista Chilena de Infectologia, Vol. 40, Núm. 6, pp. 618-625

  4. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors

    Vaccines, Vol. 11, Núm. 10

2022

  1. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 28, Núm. 2, pp. e348-e352

  2. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

    JCR: Journal of Clinical Rheumatology, Vol. 28, Núm. 2, pp. e348-e352

2021

  1. Impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases

    Vaccines, Vol. 9, Núm. 3, pp. 1-12

  2. Measuring Choroid Thickness as a Marker of Systemic Inflammation in Patients with Ankylosing Spondylitis

    Journal of Clinical Rheumatology, Vol. 27, Núm. 8, pp. E307-E311

  3. Protocolised odontological assessment of patients with primary Sjögren's syndrome

    Reumatologia Clinica, Vol. 17, Núm. 1, pp. 25-31

  4. Reply

    Medicina Clinica

  5. Serological response to influenza vaccine in patients with autoimmune inflammatory diseases: Results of RIER study

    Medicina Clinica, Vol. 156, Núm. 3, pp. 118-122

2020

  1. Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis

    JCR: Journal of Clinical Rheumatology

  2. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study

    Clinical Rheumatology, Vol. 39, Núm. 9, pp. 2751-2756

  3. Reproducibilidad de la medición manual del grosor coroideo utilizando la tomografía de coherencia óptica

    Archivos de la Sociedad Española de Oftalmologia, Vol. 95, Núm. 8, pp. 379-385

2019

  1. Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study

    Medicina Clinica, Vol. 153, Núm. 10, pp. 380-386

  2. Choroidal and retinal thickness in systemic autoimmune and inflammatory diseases: A review

    Survey of Ophthalmology, Vol. 64, Núm. 6, pp. 757-769

  3. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257